StockData
CNS Pharmaceuticals, Inc. logo

CNS Pharmaceuticals, Inc. (CNSP) stock

CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$4.15+0.67 (+19.25%)

Close on Nov 17, 2026Market cap $6.07MP/E –Yield –

CNS Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

CNS Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$13.41M. For fiscal 2025 it was -$13.81M. The highest annual figure on record is -$716.39K in fiscal 2018.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$13.81M–
FY2024Dec 31, 2024-$17.11M–
FY2023Dec 31, 2023-$14.14M–
FY2022Dec 31, 2022-$10.56M–
FY2021Dec 31, 2021-$13.54M–
FY2020Dec 31, 2020-$7.32M–
FY2019Dec 31, 2019-$3.55M–
FY2018Dec 31, 2018-$716.39K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.54M–
Q1 FY2026Mar 31, 2026-$4.65M–
Q4 FY2025Dec 31, 2025-$3.05M–
Q3 FY2025Sep 30, 2025-$2.17M–
Q2 FY2025Jun 30, 2025-$5.34M–
Q1 FY2025Mar 31, 2025-$3.24M–
Q4 FY2024Dec 31, 2024-$5.47M–
Q3 FY2024Sep 30, 2024-$6.80M–
Q2 FY2024Jun 30, 2024-$1.65M–
Q1 FY2024Mar 31, 2024-$3.19M–
Q4 FY2023Dec 31, 2023-$2.54M–
Q3 FY2023Sep 30, 2023-$3.38M–
Q2 FY2023Jun 30, 2023-$3.40M–
Q1 FY2023Mar 31, 2023-$4.82M–
Q4 FY2022Dec 31, 2022-$2.31M–
Q3 FY2022Sep 30, 2022-$1.81M–
Q2 FY2022Jun 30, 2022-$3.36M–
Q1 FY2022Mar 31, 2022-$3.08M–
Q4 FY2021Dec 31, 2021-$3.24M–
Q3 FY2021Sep 30, 2021-$2.00M–
Q2 FY2021Jun 30, 2021-$5.00M–
Q1 FY2021Mar 31, 2021-$3.31M–
Q4 FY2020Dec 31, 2020-$1.45M–
Q3 FY2020Sep 30, 2020-$1.27M–
Q2 FY2020Jun 30, 2020-$2.74M–
Q1 FY2020Mar 31, 2020-$1.86M–
Q4 FY2019Dec 31, 2019-$2.48M–
Q3 FY2019Sep 30, 2019-$378.32K–
Q2 FY2019Jun 30, 2019-$616.89K–
Q1 FY2019Mar 31, 2019-$82.69K–
Q4 FY2018Dec 31, 2018-$159.49K–

More CNS Pharmaceuticals figures

See a number that looks wrong?